Patented transdermal drug candidate from Vascarta may offer a convenient & cost-effective way to treat sickle cell disease

Posted on by

SUMMIT, N.J., Feb. 18, 2025 /PRNewswire/ — An article in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal* by Goel et al. describes studies in which humanized sickle cell mice topically treated with Vascarta’s transdermal curcumin gel formulation (“VAS-101”)…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.